Key statistics
As of last trade Zymeworks Inc (ZA8:FRA) traded at 18.80, -21.67% below its 52-week high of 24.00, set on Dec 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 18.80 |
|---|---|
| High | 18.80 |
| Low | 18.80 |
| Bid | 18.90 |
| Offer | 19.90 |
| Previous close | 18.40 |
| Average volume | 19.33 |
|---|---|
| Shares outstanding | 74.84m |
| Free float | 71.45m |
| P/E (TTM) | -- |
| Market cap | 1.70bn USD |
| EPS (TTM) | -0.8448 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 08:55 GMT.
More ▼
Announcements
- Zymeworks Announces Participation in Upcoming Investor Conferences
- Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
- Zymeworks Outlines Strategic Priorities and Outlook for 2026
- Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
- Zymeworks Announces Participation in Upcoming Conferences
- Zymeworks Announces Participation in Upcoming Investor Conferences
- Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
- Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
- Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
- Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
More ▼
